| Drug Name |
Brigatinib |
| Drug ID |
BADD_D02509 |
| Description |
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type.[A31311] It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma.[A31313] Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.[L1026] |
| Indications and Usage |
The anaplastic lymphoma kinase positive, metastatic non-small cell lung cancer (ALK+ NSCLC), represents only 3-5% of the NSCLC cancer cases, but the ALK mutation, overexpression and presence in several oncogenic fusion proteins in solid and hematologic tumors have pointed out the importance as well as its potential as a cancer therapy target.[A31311] The ALK-related cases of NSCLC are associated with the presence of the fusion gene EML4-ALK which fused the ALK protein with the echinoderm microtubule-associated protein like-4 whose original function is the correct formation of microtubules.[A31313] The presence of the aberrant fusion protein results in abnormal signaling that provokes increased cell growth, proliferation and survival.[A31316] Crizotinib is indicated for the treatment of such cases but the presence of ALK kinase domain mutations confer resistance to the treatment. Thus, brigatinib is indicated for the treatment of patients with ALK+ NSCLC with intolerance to Crizotinib.[A31314] |
| Marketing Status |
approved; investigational |
| ATC Code |
L01ED04 |
| DrugBank ID |
DB12267
|
| KEGG ID |
D10866
|
| MeSH ID |
C000598580
|
| PubChem ID |
68165256
|
| TTD Drug ID |
D08PIE
|
| NDC Product Code |
63020-180; 50683-0420; 63020-198; 63020-090; 65392-3311; 63020-113 |
| UNII |
HYW8DB273J
|
| Synonyms |
brigatinib | Alunbrig | AP26113 |
